Otoferlin Gene-mediated Hearing Loss

DBCOND0170571Congenital, Hereditary, and Neonatal Diseases and AbnormalitiesOtorhinolaryngologic Diseases

Otoferlin Gene-mediated Hearing Loss is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) · Otoferlin-related Auditory Synaptopathy · Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF)
Classified under
Indicated drugs

What you can answer from here — as of October 23, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not prose
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1Drug reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Otoferlin Gene-mediated Hearing Loss share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In